DSpace About DSpace Software 日本語

01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2020年度 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/3781

Title: Combining probiotics and an angiotensin-II type 1 receptor blocker has beneficial effects on hepatic fibrogenesis in a rat model of non-alcoholic steatohepatitis.
Other Titles: ラット非アルコール性脂肪肝炎モデルに対するプロバイオティクスとアンギオテンシンⅡ受容体拮抗薬併用療法の肝線維化に対する有効性
Authors: Sawada, Yasuhiko
Kawaratani, Hideto
Kubo, Takuya
Fujinaga, Yukihisa
Furukawa, Masanori
Saikawa, Soichiro
Sato, Shinya
Seki, Kenichiro
Takaya, Hiroaki
Okura, Yasushi
Kaji, Kosuke
Shimozato, Naotaka
Mashitani, Tsuyoshi
Kitade, Mitsuteru
Moriya, Kei
Namisaki, Tadashi
Akahane, Takemi
Mitoro, Akira
Yamao, Junichi
Yoshiji, Hitoshi
Keywords: angiotensin‐II type 1 receptor blocker (ARB)
hepatic fibrosis
intestinal tight junction
non‐alcoholic steatohepatitis
Issue Date: Mar-2019
Publisher: Wiley
Citation: Hepatology research Vol.49 No.3 p.284-295 (2020 Mar)
Abstract: Aim: Intestinal endotoxin is important for the progression of non-alcoholic steatohepatitis (NASH). Circulating endotoxin levels are elevated in most animal models of diet-induced non-alcoholic fatty liver disease (NAFLD) and NASH. Furthermore, plasma endotoxin levels are significantly higher in NAFLD patients, which is associated with small intestinal bacterial overgrowth and increased intestinal permeability. By improving the gut microbiota environment and restoring gut-barrier functions, probiotics are effective for NASH treatment in animal models. It is also widely known that hepatic fibrosis and suppression of activated hepatic stellate cells (Ac-HSCs) can be attenuated using an angiotensin-II type 1 receptor blocker (ARB). We thus evaluated the effect of combination probiotics and ARB treatment on liver fibrosis using a rat model of NASH. Methods: Fisher 344 rats were fed a choline-deficient/L-amino acid-defined (CDAA) diet for 8 weeks to generate the NASH model. Animals were divided into ARB, probiotics, and ARB plus probiotics groups. Therapeutic efficacy was assessed by evaluating liver fibrosis, the lipopolysaccharide Toll-like receptor (TLR)4 regulatory cascade, and intestinal barrier function. Results: Both probiotics and ARB inhibited liver fibrosis, with concomitant HSC activation and suppression of liver-specific transforming growth factor-β and TLR4 expression. Probiotics reduced intestinal permeability by rescuing zonula occludens-1 disruption induced by the CDAA diet. Angiotensin-II type 1 receptor blocker was found to directly suppress Ac-HSCs. Conclusions: Probiotics and ARB are effective in suppressing liver fibrosis through different mechanisms. Currently both drugs are in clinical use; therefore, the combination of probiotics and ARB is a promising new therapy for NASH.
Description: 博士(医学)・乙第1465号・令和2年9月30日
© 2018 The Japan Society of Hepatology
This is the pre-peer reviewed version of the following article: [https://onlinelibrary.wiley.com/doi/full/10.1111/hepr.13281], which has been published in final form at [https://doi.org/10.1111/hepr.13281]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
URI: http://hdl.handle.net/10564/3781
ISSN: 13866346
Academic Degrees and number: 24601B1465
Degree-granting date: 2020-09-30
Degree name: 博士(医学)
Degree-granting institutions: 奈良県立医科大学
Appears in Collections:2020年度

Files in This Item:

File Description SizeFormat
01乙1465本文の要旨.pdf乙1465本文の要旨1.73 MBAdobe PDFView/Open
02乙1465審査要旨.pdf乙1465審査要旨320.28 kBAdobe PDFView/Open
03乙1465本文.pdf乙1465本文2.44 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback